ARAC 02
Alternative Names: ARAC-02; ARAC™ - Pdx PharmaceuticalsLatest Information Update: 07 Sep 2023
Price :
$50 *
At a glance
- Originator PDX Pharmaceuticals
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Polo-like kinase 1 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Toll-like receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Small cell lung cancer
Most Recent Events
- 14 Jun 2023 Pdx Pharmaceuticlas receives SBIR grant from National Cancer Institute (NCI) for ARAC 02 development in Non small cell lung cancer
- 14 Apr 2023 Preclinical trials in Small cell lung cancer in USA (parenteral), prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from preclinical studies in Non small cell lung cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)